Amantadine Hydrochloride

盐酸金刚烷胺

Report date: 2026/04/18 20:00:19
NME

Base Information

Drug NameAmantadine Hydrochloride
Drug Alias Name盐酸金刚胺ADA (Universite Libre de Bruxelles)Adamantamine HydrochlorideLysovirOsmolex ER +[16] 
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Drug-induced extrapyramidal reactions +[17] 
Global Approved IndicationsInfluenza A virus infectionsDrug-induced extrapyramidal reactionsParkinson Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1968/02/14
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityShahid Beheshti University Of Medical SciencesSupernus Pharmaceuticals Inc +[5] 
Inactive CompaniesNoblewellUniversity of Texas Southwestern Medical CenterUniversity Of Manitoba +[8] 
Active IndicationsHemorrhagic StrokeIschemic StrokePost-Acute COVID-19 Syndrome +[7] 
Inactive IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Drug-induced extrapyramidal reactions +[10] 

Other Information

ATC CodeN04BB01
Related LinksWikipediaDrugBankKEGG